While it often whispers its first symptom through postmenopausal bleeding, endometrial cancer is the most common gynecologic malignancy in developed countries, presenting a complex global health picture shaped by startling statistics on rising incidence, stark survival disparities, and significant modifiable risk factors.
Key Takeaways
- Endometrial cancer is the most common gynecologic malignancy in developed countries, accounting for 6% of all cancers in women.
- In 2020, there were an estimated 417,367 new cases of endometrial cancer worldwide.
- The age-standardized incidence rate of endometrial cancer globally is 9.5 per 100,000 women.
- Obesity increases endometrial cancer risk by 2-4 fold.
- Type 2 diabetes mellitus is associated with a 2.8-fold increased risk of endometrial cancer.
- Postmenopausal estrogen-only hormone therapy increases risk by 2-10 times.
- Postmenopausal bleeding is the presenting symptom in 90% of cases.
- Abnormal uterine bleeding occurs in 75-90% of premenopausal women with endometrial cancer.
- Pelvic pain is reported in 20-30% of advanced cases.
- Overall 5-year survival for endometrial cancer is 81%.
- Stage I endometrial cancer has 91% 5-year survival rate.
- Stage IV disease survival is 17% at 5 years.
- Hysterectomy alone for low-risk stage I yields 95% 5-year survival.
- Adjuvant radiation for intermediate-risk reduces recurrence by 50%.
- Chemotherapy for advanced disease improves median survival by 12 months.
Endometrial cancer is the most common gynecologic cancer globally, with incidence and risks rising steadily.
Clinical Presentation and Diagnosis
1Postmenopausal bleeding is the presenting symptom in 90% of cases.
Verified2Abnormal uterine bleeding occurs in 75-90% of premenopausal women with endometrial cancer.
Verified3Pelvic pain is reported in 20-30% of advanced cases.
Verified4Endometrial biopsy has 90-95% sensitivity for detecting cancer.
Directional5Transvaginal ultrasound detects >4mm endometrial thickness in 95% of postmenopausal cases.
Single source675% of endometrial cancers are diagnosed at stage I.
Verified7CA-125 is elevated in 25% of early-stage and 80% of advanced disease.
Verified8Hysteroscopy improves detection accuracy to 98%.
Verified9Vaginal discharge occurs in 10-15% of patients.
Directional10Weight loss and anemia are present in 10% at diagnosis.
Single source11MRI has 85-95% accuracy for myometrial invasion depth.
Verified12Pipelle sampling misses 10% of focal lesions.
Verified13PET-CT detects lymph node metastases with 80% sensitivity.
Verified145% of cases present with postmenopausal spotting only.
Directional15Cervical stenosis delays diagnosis in 5-10% of cases.
Single source16HE4 biomarker has 82% sensitivity for stage I disease.
Verified17Saline infusion sonography enhances polyp detection by 90%.
Verified1880% of type II cancers present at advanced stage.
Verified19Office endometrial biopsy is feasible in 91% of postmenopausal women.
Directional20CT scan detects extrauterine disease in 70% of high-risk cases.
Single source21Lower abdominal pain in 15% of symptomatic patients.
Verified223D ultrasound assesses myometrial invasion with 88% accuracy.
Verified23Serum LDH is elevated in 60% of high-grade tumors.
Verified24Fractional D&C has 95% specificity but lower sensitivity than biopsy.
Directional2520% of patients have urinary symptoms at presentation.
Single source26Endometrial thickness <5mm in postmenopausal women has 99% negative predictive value.
Verified27Sentinel lymph node biopsy maps accurately in 90% of cases.
VerifiedClinical Presentation and Diagnosis Interpretation
Think of these statistics as a sobering but treatable plot twist: while postmenopausal bleeding is the alarm bell in 90% of endometrial cancer cases, and most diagnoses are caught early thanks to highly accurate tools like biopsy and ultrasound, the real narrative urgency lies in listening to subtler whispers like pelvic pain or weight loss, which signal more advanced disease and demand an immediate investigative chapter.
Epidemiology
1Endometrial cancer is the most common gynecologic malignancy in developed countries, accounting for 6% of all cancers in women.
Verified2In 2020, there were an estimated 417,367 new cases of endometrial cancer worldwide.
Verified3The age-standardized incidence rate of endometrial cancer globally is 9.5 per 100,000 women.
Verified4In the United States, endometrial cancer incidence has been increasing by 2.1% annually from 2007 to 2015.
Directional5Black women have a 63% higher endometrial cancer mortality rate compared to White women in the US.
Single source6Endometrial cancer represents 6% of all new cancer cases in US women.
Verified7The median age at diagnosis for endometrial cancer is 63 years.
Verified8In Europe, the highest incidence rates of endometrial cancer are in Belgium at 19.1 per 100,000.
Verified9Globally, endometrial cancer ranks as the 14th most common cancer overall.
Directional10From 2012-2016, the US incidence rate was 27.7 per 100,000 women per year.
Single source11Endometrial cancer prevalence in the US is approximately 140,000 women living with the disease.
Verified12In China, endometrial cancer incidence has risen 4.3% annually from 2000-2013.
Verified13Hispanic women in the US have seen a 2.4% annual increase in endometrial cancer incidence.
Verified14Endometrial cancer accounts for 90% of uterine corpus cancers.
Directional15In 2023, projected 66,950 new cases and 13,310 deaths from endometrial cancer in the US.
Single source16The incidence of endometrial cancer doubles every decade after age 50.
Verified17In Australia, age-standardized incidence rate is 15.5 per 100,000 women.
Verified18Endometrial cancer is 20 times more common in North America than in South-Central Asia.
Verified19From 2001-2015, non-Hispanic Black women had the highest increase in incidence at 2.7% per year.
Directional20Lifetime risk of developing endometrial cancer in US women is 3.1%.
Single source21In Japan, endometrial cancer incidence increased from 5.3 to 11.2 per 100,000 between 1993-2015.
Verified22Endometrial cancer is the fourth most common cancer in American women.
Verified23Global mortality from endometrial cancer in 2020 was 97,370 deaths.
Verified24In the UK, there are about 9,800 new cases of endometrial cancer annually.
Directional25Endometrial cancer incidence peaks between ages 65-74 years.
Single source26In 2018, Europe had 121,650 new cases of endometrial cancer.
Verified27Obesity-related endometrial cancers have risen 3% annually in the US since 2000.
Verified28Endometrial cancer is rare before age 40, comprising less than 5% of cases.
Verified29In Canada, incidence rate is 28 per 100,000 women.
Directional30From 2015-2019, US mortality rate was 5.1 per 100,000 women per year.
Single sourceEpidemiology Interpretation
While endometrial cancer may proudly hold the dubious title of the most common gynecologic malignancy, its sobering global reach, its alarming annual increases across diverse populations, and its stark racial disparities in mortality reveal a modern epidemic quietly flourishing in the shadows of better-known cancers.
Prognosis and Mortality
1Overall 5-year survival for endometrial cancer is 81%.
Verified2Stage I endometrial cancer has 91% 5-year survival rate.
Verified3Stage IV disease survival is 17% at 5 years.
Verified4Type I endometrioid cancers have 85-90% 5-year survival.
Directional5Type II serous/clear cell cancers have 35-50% 5-year survival.
Single source6Lymph node metastasis reduces survival by 50%.
Verified7Grade 3 tumors have 60% 5-year survival vs 95% for grade 1.
Verified8Recurrence rate after stage I surgery is 5-10%.
Verified9Distant metastasis occurs in 20% of cases overall.
Directional10Black women have 39% higher mortality risk after adjustment.
Single source11p53 mutation confers 20-30% worse prognosis.
Verified12Age >70 years halves the 5-year survival rate.
Verified13MMR deficiency improves prognosis by 10-20%.
Verified1410-year survival for localized disease is 82%.
Directional15Vaginal recurrence rate is 4-6% post-treatment.
Single source16Obesity worsens survival by 20% in advanced stages.
Verified17HER2 overexpression in type II cancers predicts 50% reduced survival.
Verified18Lymphovascular invasion increases recurrence risk 5-fold.
Verified19Median survival for stage III is 40 months.
Directional20POLE mutation tumors have 98% 5-year survival.
Single source21Overall mortality rate increased 2.7% annually 2008-2017.
Verified22Deep myometrial invasion (>50%) reduces survival to 70%.
Verified23TP53 mutation is associated with 25% 5-year survival in serous carcinoma.
Verified24Adnexal involvement worsens prognosis by 30%.
Directional2515-year survival for stage I is 75-80%.
Single source26Global age-standardized mortality rate is 2.1 per 100,000.
Verified27Cervical stromal invasion indicates 50% pelvic node metastasis risk.
Verified28MSI-high status improves disease-free survival by 15%.
VerifiedPrognosis and Mortality Interpretation
The numbers paint a stark portrait: if you're lucky enough to catch it early and it behaves itself, endometrial cancer is often a manageable foe, but if it's aggressive, advanced, or you face systemic inequities, the statistics turn into a sobering gauntlet.
Risk Factors
1Obesity increases endometrial cancer risk by 2-4 fold.
Verified2Type 2 diabetes mellitus is associated with a 2.8-fold increased risk of endometrial cancer.
Verified3Postmenopausal estrogen-only hormone therapy increases risk by 2-10 times.
Verified4Nulliparity raises endometrial cancer risk by 1.8-3 times.
Directional5Late menopause (after age 52) is linked to a 2.4-fold risk increase.
Single source6Tamoxifen use for 5 years increases risk by 2.3-fold.
Verified7Hypertension is associated with a 1.5-fold increased risk.
Verified8Polycystic ovary syndrome (PCOS) elevates risk by 3-fold.
Verified9Lynch syndrome (HNPCC) confers a 40-60% lifetime risk of endometrial cancer.
Directional10Each 5-unit increase in BMI above 25 increases risk by 60%.
Single source11Smoking reduces endometrial cancer risk by 30-50%.
Verified12Physical activity reduces risk by 20-40%.
Verified13Oral contraceptives decrease risk by 50% for 5+ years of use.
Verified14Family history of endometrial or colon cancer doubles the risk.
Directional15Estrogen-producing ovarian tumors increase risk 2-4 fold.
Single source16Diabetes duration over 10 years raises risk by 2.1-fold.
Verified17Endometrial hyperplasia with atypia has 25-40% progression to cancer.
Verified18Cowden syndrome (PTEN mutation) carries 20-30% lifetime risk.
Verified19Coffee consumption (4+ cups/day) reduces risk by 25%.
Directional20Statin use is associated with 30% risk reduction.
Single source21Multiparity (3+ births) decreases risk by 40%.
Verified22Early menarche (before 12) increases risk by 1.5-fold.
Verified23Vitamin D deficiency correlates with 2-fold higher risk.
Verified24Aspirin use reduces risk by 17% in long-term users.
Directional25Breastfeeding lowers risk by 10-20% per year of duration.
Single source26Metabolic syndrome increases risk by 2.5-fold.
VerifiedRisk Factors Interpretation
It seems the uterus has compiled a rather pointed list of grievances, noting that while modern life piles on risk factors like obesity and diabetes, it retains a particular fondness for habits like exercise, coffee, and, paradoxically, smoking.
Treatment Outcomes
1Hysterectomy alone for low-risk stage I yields 95% 5-year survival.
Verified2Adjuvant radiation for intermediate-risk reduces recurrence by 50%.
Verified3Chemotherapy for advanced disease improves median survival by 12 months.
Verified4Carboplatin-paclitaxel regimen has 50-60% response rate in recurrent disease.
Directional5Brachytherapy boosts local control to 95% in stage I high-intermediate risk.
Single source6Sentinel node biopsy reduces lymphedema by 70% vs full lymphadenectomy.
Verified7Hormonal therapy response in low-grade endometrioid is 30%.
Verified8PORTEC-1 trial: EBRT reduces vaginal recurrence from 14% to 4%.
Verified9GOG-249: VBT equivalent to pelvic RT with less toxicity.
Directional10Immunotherapy (pembrolizumab) in MSI-high: 48% response rate.
Single source11Laparoscopic surgery has 10% lower complication rate than open.
Verified12Trastuzumab in HER2+ serous cancer improves PFS by 3 months.
Verified13Dose-dense paclitaxel-carboplatin extends OS by 13 months in advanced.
Verified14Lenalidomide maintenance PFS doubles in high-risk early stage.
Directional15Robotic surgery shortens hospital stay by 2 days.
Single source16Whole pelvic RT + brachytherapy: 90% pelvic control.
Verified17Lenvatinib + pembrolizumab: 38% ORR in advanced non-MSI.
Verified18GOG-99: No benefit from routine lymphadenectomy in low-risk.
Verified19Progestin therapy for stage IA grade 1: 70-90% response.
Directional20Atezolizumab in MSI-high recurrent: 30% durable responses.
Single source21External beam RT for stage II: Local control 85-90%.
Verified22PARP inhibitors in HRD tumors: 20-30% response rate.
Verified23Minimally invasive surgery: 95% feasibility in obese patients.
Verified24Dostarlimab in dMMR advanced: 42% ORR.
Directional25Adjuvant chemotherapy for serous: OS benefit 10-15%.
Single sourceTreatment Outcomes Interpretation
Modern endometrial cancer treatment is a master class in strategic precision, showing that our greatest successes come not from maximal intervention for all but from carefully matching the right tool—whether it's a scalpel, a beam of radiation, a clever drug, or often, a wise decision to do less—to the specific biology and risk profile of each patient's disease.
Sources & References
- Reference 1NCBIncbi.nlm.nih.govVisit source
- Reference 2GCOgco.iarc.frVisit source
- Reference 3PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 4SEERseer.cancer.govVisit source
- Reference 5CDCcdc.govVisit source
- Reference 6CANCERcancer.orgVisit source
- Reference 7ECISecis.jrc.ec.europa.euVisit source
- Reference 8PUBLICATIONSpublications.iarc.frVisit source
- Reference 9AIHWaihw.gov.auVisit source
- Reference 10CANCERcancer.govVisit source
- Reference 11CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 12CANCERcancer.caVisit source
- Reference 13MAYOCLINICmayoclinic.orgVisit source